Clinical implications for nonproprietary medicines in #multiplesclerosis: focus on fingolimod https://t.co/aaTbwhn19G #Neurology
RT @OhioHealthMS: Clinical implications for substandard, nonproprietary (i.e. generic) medicines in #MS: focus on fingolimod https://t.co/x…
RT @OhioHealthMS: Clinical implications for substandard, nonproprietary (i.e. generic) medicines in #MS: focus on fingolimod https://t.co/x…
PubMed: Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod. https://t.co/21cLqqmqa5
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod. https://t.co/ZoYHaaIPw5
Clinical implications for substandard, nonproprietary (i.e. generic) medicines in #MS: focus on fingolimod https://t.co/xYu6BGv5gZ
Clinical implications for substandard nonproprietary medicines in MS https://t.co/EXwNFYHXOc